PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 62 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $197,349 | -68.3% | 63,867 | -53.9% | 0.00% | – |
| Q2 2023 | $623,218 | +80005.1% | 138,493 | +1.4% | 0.00% | – |
| Q1 2023 | $778 | +159.3% | 136,519 | +174.5% | 0.00% | – |
| Q4 2022 | $300 | -99.9% | 49,736 | -17.7% | 0.00% | – |
| Q3 2022 | $399,000 | -16.0% | 60,426 | -33.6% | 0.00% | – |
| Q2 2022 | $475,000 | +75.3% | 90,937 | +131.3% | 0.00% | – |
| Q1 2022 | $271,000 | -95.1% | 39,311 | -91.1% | 0.00% | -100.0% |
| Q4 2021 | $5,529,000 | +333.0% | 444,111 | +987.1% | 0.00% | +200.0% |
| Q3 2021 | $1,277,000 | +112.8% | 40,851 | +94.9% | 0.00% | – |
| Q2 2021 | $600,000 | +2.6% | 20,958 | +55.2% | 0.00% | – |
| Q1 2021 | $585,000 | -89.8% | 13,503 | -92.9% | 0.00% | -100.0% |
| Q3 2020 | $5,712,000 | – | 189,573 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $287,436,000 | 2.91% |
| Baker Brothers Advisors | 10,123,824 | $289,845,000 | 1.27% |
| Logos Global Management LP | 400,000 | $11,452,000 | 0.96% |
| Rock Springs Capital Management LP | 382,359 | $10,947,000 | 0.22% |
| HHLR ADVISORS, LTD. | 583,333 | $16,701,000 | 0.17% |
| Virtus ETF Advisers LLC | 6,622 | $190,000 | 0.08% |
| Jump Financial, LLC | 13,700 | $392,000 | 0.04% |
| ARS Investment Partners, LLC | 7,400 | $212,000 | 0.02% |
| FEDERATED HERMES, INC. | 336,100 | $9,623,000 | 0.02% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 1,287,735 | $36,867,853,000 | 0.02% |